GlassScriptPhysician profile
Daniel R Hunting
NPI 1336710862
$5,929.58
in general payments reported to CMS, 2019-2025
31 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $304 · 2022: $448 · 2023: $760 · 2024: $3,336 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467 · Travel and Lodging: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,467.48 |
| Travel and Lodging | $1,710.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,391.96 | 2021-2025 | Symplicity G3, Resolute Onyx |
| Novartis Pharmaceuticals Corporation | $876.03 | 2021-2025 | |
| Pfizer INC. | $549.97 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $437.65 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Lexicon Pharmaceuticals, INC. | $177.29 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $155.31 | 2024 | Arcalyst |
| Boston Scientific Corporation | $141.97 | 2021-2025 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $138.69 | 2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $128.17 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $107.68 | 2022-2025 | Amvuttra |
| Daiichi Sankyo INC. | $99.47 | 2023-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $94.58 | 2021-2025 | |
| Cvrx, INC. | $89.01 | 2022-2023 | Barostim Neo System |
| Amgen INC. | $74.06 | 2024-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $59.87 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $58.49 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.95 | 2023-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $35.55 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.54 | 2023-2024 | Lifevest |
| Inspire Medical Systems, INC. | $33.71 | 2023 | Inspire |
| Lilly USA, LLC | $28.56 | 2022-2025 | Zepbound, Mounjaro |
| Regeneron Healthcare Solutions, INC. | $26.84 | 2025 | Evkeeza |
| Mannkind Corporation | $23.12 | 2025 | |
| Genzyme Corporation | $17.80 | 2024 | |
| Novo Nordisk INC | $17.42 | 2025 | Wegovy |
| Philips North America LLC | $16.55 | 2025 | Mcot |
| Mylan Specialty L.P. | $16.10 | 2024 | Yupelri |
| United Therapeutics Corporation | $14.74 | 2024 | Orenitram |
| Altathera Pharmaceuticals LLC | $14.22 | 2024 | Sotalol Hydrochloride |
| Kiniksa Pharmaceuticals, LTD. | $12.88 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hunting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.